

Nanologica Announces Outcome of Directed Share Issues

Nanologica AB (publ) ("Nanologica" or "the Company") hereby announces the outcome of the two directed issues of shares resolved by the board of directors on 30 January 2026 and approved by the extraordinary general meeting on 4 March 2026. The directed issues comprised a total of 34,203,780 shares. All shares have been subscribed for and allotted in accordance with the resolutions.

Ardena Sweden AB has subscribed for and been allotted all 21,453,780 shares in the set-off issue. The subscription price was SEK 0.40 per share, corresponding to a total subscription amount of approximately SEK 8.6 million, which was settled by set-off.

The directed issue of 12,750,000 shares has been fully subscribed and allotted to a limited group of investors at a subscription price of SEK 0.40 per share, which means that the Company will receive issue proceeds of approximately SEK 5.1 million before deductions of costs attributable to the issue. For further information on the directed new issues, please refer to the separate press release dated 30 January 2026.

For further information, please contact

Johanna Johansson
Director IR, Communications and Marketing
johanna.johansson@nanologica.com
+46 72 211 21 90

About Nanologica AB (publ)

Nanologica is a Swedish life science tools company that develops, manufactures, and sells advanced consumables to pharmaceutical manufacturers. Nanologica's products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity. The company's mission is to increase access to cost-effective drugs through its purification products and thereby contribute to more patients around the world having access to life-saving treatments. The company is headquartered in Södertälje and Nanologica's share (NICA) is listed for trading on Nasdaq Stockholm Main Market. For further information, please visit www.nanologica.com.

Attachments

[Nanologica Announces Outcome of Directed Share Issues](#)